Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable

Trial Details

NCT ID
NCT07130903
Phase
PHASE2
Sponsor
Barbara Ann Karmanos Cancer Institute
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Fruquintinib
  • TheraBionic P1
Locations (sample)
  • Bay City, Michigan, United States|43.59447,-83.88886
  • Clarkston, Michigan, United States|42.73586,-83.41883
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Flint, Michigan, United States|43.01253,-83.68746
  • Lansing, Michigan, United States|42.73253,-84.55553

Key Eligibility Criteria

  • Participant must have histologically or cytologically confirmed metastatic colorectal adenocarcinoma. There must be previous documentation of RAS (…
  • Participant must have progressed on or been intolerant to the following previous treatments (if not contraindicated):
  • Fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy
  • Anti-VEGF (vascular endothelial growth factor) biological therapy, such as bevacizumab, aflibercept, or ramucirumab

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →